Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

Literature DB >> 20887828

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

Kenneth J Smith¹, Bruce Y Lee, Mary Patricia Nowalk, Mahlon Raymund, Richard K Zimmerman.

Abstract

Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20887828 PMCID： PMC2981678 DOI： 10.1016/j.vaccine.2010.09.053

Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641

22 in total

1. Pneumococcal vaccine. Efficacy and associated cost savings.

Authors: C B Gable; S S Holzer; L Engelhart; R B Friedman; F Smeltz; D Schroeder; K Baum
Journal: JAMA Date: 1990-12-12 Impact factor: 56.272

2. IOM report: patient safety--achieving a new standard for care.

Authors:
Journal: Acad Emerg Med Date: 2005-10 Impact factor: 3.451

3. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

Authors: R Scott Braithwaite; David O Meltzer; Joseph T King; Douglas Leslie; Mark S Roberts
Journal: Med Care Date: 2008-04 Impact factor: 2.983

Review 4. Insights into the interaction between influenza virus and pneumococcus.

Authors: Jonathan A McCullers
Journal: Clin Microbiol Rev Date: 2006-07 Impact factor: 26.132

Review 5. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

Authors: Katherine L O'Brien; Michael Hochman; David Goldblatt
Journal: Lancet Infect Dis Date: 2007-09 Impact factor: 25.071

6. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.

Authors: Susan B Manoff; Charles Liss; Michael J Caulfield; Rocio D Marchese; Jeffrey Silber; John Boslego; Sandra Romero-Steiner; Gowrisankar Rajam; Nina E Glass; Cynthia G Whitney; George M Carlone
Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226

7. The timing of influenza vaccination for older adults (65 years and older).

Authors: Bruce Y Lee; Julie H Y Tai; Rachel R Bailey; Kenneth J Smith
Journal: Vaccine Date: 2009-09-26 Impact factor: 3.641

8. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

Authors: E D Shapiro; A T Berg; R Austrian; D Schroeder; V Parcells; A Margolis; R K Adair; J D Clemens
Journal: N Engl J Med Date: 1991-11-21 Impact factor: 91.245

9. Toward consistency in cost-utility analyses: using national measures to create condition-specific values.

Authors: M R Gold; P Franks; K I McCoy; D G Fryback
Journal: Med Care Date: 1998-06 Impact factor: 2.983

10. Safety of revaccination with pneumococcal polysaccharide vaccine.

Authors: L A Jackson; P Benson; V P Sneller; J C Butler; R S Thompson; R T Chen; L S Lewis; G Carlone; F DeStefano; P Holder; T Lezhava; W W Williams
Journal: JAMA Date: 1999-01-20 Impact factor: 56.272

14 in total

1. Cost-effectiveness of adult vaccinations: A systematic review.

Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges
Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641

2. Quantifying the economic value and quality of life impact of earlier influenza vaccination.

Authors: Bruce Y Lee; Sarah M Bartsch; Shawn T Brown; Philip Cooley; William D Wheaton; Richard K Zimmerman
Journal: Med Care Date: 2015-03 Impact factor: 2.983

3. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine.

Authors: Bruce Y Lee; Sarah M Bartsch; Mercy Mvundura; Courtney Jarrahian; Kristina M Zapf; Kathleen Marinan; Angela R Wateska; Bill Snyder; Savitha Swaminathan; Erica Jacoby; James J Norman; Mark R Prausnitz; Darin Zehrung
Journal: Vaccine Date: 2015-03-13 Impact factor: 3.641

4. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland.

Authors: Pawel Grzesiowski; Raquel Aguiar-Ibáñez; Aleksandra Kobryń; Laure Durand; Pierre-Emmanuel Puig
Journal: Hum Vaccin Immunother Date: 2012-10-01 Impact factor: 3.452

5. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis.

Authors: Constantinos I Michaelidis; Richard K Zimmerman; Mary Patricia Nowalk; Kenneth J Smith
Journal: Value Health Date: 2013 Mar-Apr Impact factor: 5.725

10. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study.

Authors: Marc Baguelin; Anton Camacho; Stefan Flasche; W John Edmunds
Journal: BMC Med Date: 2015-10-13 Impact factor: 8.775